$AKRX Headlines Speculators live by the sword,
Post# of 89337
Posted On: 09/28/2014 10:48:46 AM
$AKRX Headlines
Speculators live by the sword, die by the sword 3:13 p.m. July 8, 2014 - The Trading Deck
Dow, Nasdaq nail the breakout point 10:36 a.m. June 27, 2014 - Michael Ashbaugh
From tiny Akorns grow mighty oaks? 11:03 a.m. Nov. 21, 2013 - The Trading Deck
Rail-Splitter's top small-cap bets are worth watching 12:34 p.m. Nov. 4, 2013 - Insider Monkey
Akorn to buy Hi-Tech for $640 million in cash 8:02 a.m. Aug. 27, 2013 - MarketWatch.com
Monday’s biggest gaining and declining stocks 4:20 p.m. July 23, 2012 - MarketWatch
Corrective bounce, or sustainable upturn? 10:59 a.m. June 6, 2012 - Michael Ashbaugh
Charting a bearish double top 12:11 p.m. May 15, 2012 - Michael Ashbaugh
Charting a bearish double top 11:45 a.m. May 15, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 6:02 p.m. March 7, 2012 - Sue Chang
Tuesday’s biggest gaining and declining stocks 5:23 p.m. March 6, 2012 - MarketWatch
Stocks to watch Tuesday: Nutrisystem, Jakks 8:00 a.m. March 6, 2012 - MarketWatch
S&P 500 scratches out three-year high 12:07 p.m. March 2, 2012 - Michael Ashbaugh
Stocks to watch Friday: LinkedIn, LeapFrog, Nuance 7:46 a.m. Feb. 10, 2012 - MarketWatch
S&P 500 vies for positive 2011 finish 12:09 p.m. Dec. 23, 2011 - Michael Ashbaugh
S&P, Nasdaq retest major support 12:51 p.m. Dec. 12, 2011 - Michael Ashbaugh
U.S. markets survive test of major support 10:57 a.m. Nov. 2, 2011 - Michael Ashbaugh
Akorn rallies on earnings, M&A deal 1:59 p.m. Aug. 2, 2011 - Val Brickates Kennedy
Drug stocks slip; Emergent rallies 1:28 p.m. May 26, 2011 - Val Brickates Kennedy
Drug stocks gain; Derma, Elan climb 3:51 p.m. May 25, 2011 - Val Brickates Kennedy
Meet 5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 26, 2014 - Investors Business Daily
Progenics' Azedra Found Positive in Phase II Follow-Up Data - Analyst Blog 6:10 p.m. Sept. 23, 2014 - Zacks.com
Supernus Confirms 2014 Outlook, Epilepsy Products in Focus - Analyst Blog 4:55 p.m. Sept. 23, 2014 - Zacks.com
Acquisition-Hungry Akorn Sets Up Potential Buy Area 5:10 p.m. Sept. 22, 2014 - Investors Business Daily
Analysts Are Warming to These 5 Stocks 9:25 a.m. Sept. 22, 2014 - InvestorPlace.com
IBD 50: Akorn Aims For $1 Billion In Sales 5:35 p.m. Sept. 19, 2014 - Investors Business Daily
IBD 50 Stocks Setting Up, Including These 5 Medicals 5:35 p.m. Sept. 19, 2014 - Investors Business Daily
Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog 4:30 p.m. Sept. 18, 2014 - Zacks.com
Will Drugmaker Akorn Have A Healthy Bounce Up? 11:09 a.m. Sept. 18, 2014 - Investors Business Daily
Stocks with Upgraded Broker Ratings - Screen of the Week 3:57 a.m. Sept. 16, 2014 - Zacks.com
AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog 5:05 p.m. Sept. 12, 2014 - Zacks.com
5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 12, 2014 - Investors Business Daily
Wall Street Breakfast: EU Places New Sanctions On Russia, U.S. To Follow 6:32 a.m. Sept. 12, 2014 - Seeking Alpha
Akorn In Second Test Of 10-Week Line 5:09 p.m. Sept. 11, 2014 - Investors Business Daily
Akorn reportedly eyeing tax inversion deal 4:07 p.m. Sept. 11, 2014 - Seeking Alpha
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog 4:45 p.m. Sept. 10, 2014 - Zacks.com
10 Stocks with 5-Year Returns of 1,500%-Plus 5:10 a.m. Sept. 10, 2014 - InvestorPlace.com
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog 5:20 p.m. Sept. 8, 2014 - Zacks.com
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog 5:05 p.m. Sept. 5, 2014 - Zacks.com
Salix, Gilead Among 5 Top Medical Leaders To Watch 4:06 p.m. Sept. 5, 2014 - Investors Business Daily
Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma 9:25 a.m. Sept. 8, 2014 - PR Newswire - PRF
Restaurant Openings, Financial Releases, Completed Projects, Regulatory Updates, and Strategic Acquisitions - Research Reports on El Pollo Loco, SunEdison, Workday, PCG and Akorn 8:30 a.m. Sept. 5, 2014 - PR Newswire - PRF
Akorn Completes Acquisition of VersaPharm 8:51 a.m. Aug. 12, 2014 - GlobeNewswire
Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed 9:20 a.m. Aug. 7, 2014 - PR Newswire - PRF
Akorn Reports Preliminary 2014 Second Quarter Results 6:05 a.m. Aug. 5, 2014 - GlobeNewswire
Global Parkinson%s Disease Market 2014-2018 6:42 p.m. July 28, 2014 - PR Newswire - PRF
Akorn, Inc. Announces Second Quarter 2014 Earnings Release and Conference Call Information 11:34 a.m. July 15, 2014 - GlobeNewswire
Early Briefing on Pharma Stocks -- Research on Novartis, Akorn, Horizon Pharma, and Mallinckrodt 6:50 a.m. July 2, 2014 - PR Newswire - PRF
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 6:40 a.m. June 27, 2014 - PR Newswire - PRF
Akorn Divests ECR Pharmaceuticals to Valeant 11:11 a.m. June 20, 2014 - BusinessWire - BZX
Aerie Pharmaceuticals Names Craig R. Skenes as Vice President, Business Development 4:05 p.m. June 16, 2014 - BusinessWire - BZX
Pharma Stocks Review -- Research on Akorn, Questcor Pharma, Nektar Therapeutics, and Endocyte 8:00 a.m. June 5, 2014 - PR Newswire - PRF
Financial Results, Acquisition Agreement, and Investor Meeting - Analyst Notes on Zoetis, Horizon Pharma, Akorn, Furiex and Medicines Co. 7:20 a.m. May 16, 2014 - PR Newswire - PRF
Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn 11:30 a.m. May 9, 2014 - PR Newswire - PRF
Akorn to Acquire VersaPharm for $440 Million 9:19 a.m. May 9, 2014 - BusinessWire - BZX
Akorn Reports 2014 First Quarter Results 7:03 a.m. May 6, 2014 - BusinessWire - BZX
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts 8:00 a.m. April 25, 2014 - PR Newswire - PRF
Actavis to Acquire Four Products from Akorn 4:15 p.m. April 17, 2014 - PR Newswire - PRF
Akorn Completes Acquisition of Hi-Tech Pharmacal 9:21 a.m. April 17, 2014 - BusinessWire - BZX
Repligen Corporation Set to Join the S&P SmallCap 600 5:53 p.m. April 15, 2014 - PR Newswire - PRF
Speculators live by the sword, die by the sword 3:13 p.m. July 8, 2014 - The Trading Deck
Dow, Nasdaq nail the breakout point 10:36 a.m. June 27, 2014 - Michael Ashbaugh
From tiny Akorns grow mighty oaks? 11:03 a.m. Nov. 21, 2013 - The Trading Deck
Rail-Splitter's top small-cap bets are worth watching 12:34 p.m. Nov. 4, 2013 - Insider Monkey
Akorn to buy Hi-Tech for $640 million in cash 8:02 a.m. Aug. 27, 2013 - MarketWatch.com
Monday’s biggest gaining and declining stocks 4:20 p.m. July 23, 2012 - MarketWatch
Corrective bounce, or sustainable upturn? 10:59 a.m. June 6, 2012 - Michael Ashbaugh
Charting a bearish double top 12:11 p.m. May 15, 2012 - Michael Ashbaugh
Charting a bearish double top 11:45 a.m. May 15, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 6:02 p.m. March 7, 2012 - Sue Chang
Tuesday’s biggest gaining and declining stocks 5:23 p.m. March 6, 2012 - MarketWatch
Stocks to watch Tuesday: Nutrisystem, Jakks 8:00 a.m. March 6, 2012 - MarketWatch
S&P 500 scratches out three-year high 12:07 p.m. March 2, 2012 - Michael Ashbaugh
Stocks to watch Friday: LinkedIn, LeapFrog, Nuance 7:46 a.m. Feb. 10, 2012 - MarketWatch
S&P 500 vies for positive 2011 finish 12:09 p.m. Dec. 23, 2011 - Michael Ashbaugh
S&P, Nasdaq retest major support 12:51 p.m. Dec. 12, 2011 - Michael Ashbaugh
U.S. markets survive test of major support 10:57 a.m. Nov. 2, 2011 - Michael Ashbaugh
Akorn rallies on earnings, M&A deal 1:59 p.m. Aug. 2, 2011 - Val Brickates Kennedy
Drug stocks slip; Emergent rallies 1:28 p.m. May 26, 2011 - Val Brickates Kennedy
Drug stocks gain; Derma, Elan climb 3:51 p.m. May 25, 2011 - Val Brickates Kennedy
Meet 5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 26, 2014 - Investors Business Daily
Progenics' Azedra Found Positive in Phase II Follow-Up Data - Analyst Blog 6:10 p.m. Sept. 23, 2014 - Zacks.com
Supernus Confirms 2014 Outlook, Epilepsy Products in Focus - Analyst Blog 4:55 p.m. Sept. 23, 2014 - Zacks.com
Acquisition-Hungry Akorn Sets Up Potential Buy Area 5:10 p.m. Sept. 22, 2014 - Investors Business Daily
Analysts Are Warming to These 5 Stocks 9:25 a.m. Sept. 22, 2014 - InvestorPlace.com
IBD 50: Akorn Aims For $1 Billion In Sales 5:35 p.m. Sept. 19, 2014 - Investors Business Daily
IBD 50 Stocks Setting Up, Including These 5 Medicals 5:35 p.m. Sept. 19, 2014 - Investors Business Daily
Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog 4:30 p.m. Sept. 18, 2014 - Zacks.com
Will Drugmaker Akorn Have A Healthy Bounce Up? 11:09 a.m. Sept. 18, 2014 - Investors Business Daily
Stocks with Upgraded Broker Ratings - Screen of the Week 3:57 a.m. Sept. 16, 2014 - Zacks.com
AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog 5:05 p.m. Sept. 12, 2014 - Zacks.com
5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 12, 2014 - Investors Business Daily
Wall Street Breakfast: EU Places New Sanctions On Russia, U.S. To Follow 6:32 a.m. Sept. 12, 2014 - Seeking Alpha
Akorn In Second Test Of 10-Week Line 5:09 p.m. Sept. 11, 2014 - Investors Business Daily
Akorn reportedly eyeing tax inversion deal 4:07 p.m. Sept. 11, 2014 - Seeking Alpha
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog 4:45 p.m. Sept. 10, 2014 - Zacks.com
10 Stocks with 5-Year Returns of 1,500%-Plus 5:10 a.m. Sept. 10, 2014 - InvestorPlace.com
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog 5:20 p.m. Sept. 8, 2014 - Zacks.com
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog 5:05 p.m. Sept. 5, 2014 - Zacks.com
Salix, Gilead Among 5 Top Medical Leaders To Watch 4:06 p.m. Sept. 5, 2014 - Investors Business Daily
Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma 9:25 a.m. Sept. 8, 2014 - PR Newswire - PRF
Restaurant Openings, Financial Releases, Completed Projects, Regulatory Updates, and Strategic Acquisitions - Research Reports on El Pollo Loco, SunEdison, Workday, PCG and Akorn 8:30 a.m. Sept. 5, 2014 - PR Newswire - PRF
Akorn Completes Acquisition of VersaPharm 8:51 a.m. Aug. 12, 2014 - GlobeNewswire
Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed 9:20 a.m. Aug. 7, 2014 - PR Newswire - PRF
Akorn Reports Preliminary 2014 Second Quarter Results 6:05 a.m. Aug. 5, 2014 - GlobeNewswire
Global Parkinson%s Disease Market 2014-2018 6:42 p.m. July 28, 2014 - PR Newswire - PRF
Akorn, Inc. Announces Second Quarter 2014 Earnings Release and Conference Call Information 11:34 a.m. July 15, 2014 - GlobeNewswire
Early Briefing on Pharma Stocks -- Research on Novartis, Akorn, Horizon Pharma, and Mallinckrodt 6:50 a.m. July 2, 2014 - PR Newswire - PRF
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 6:40 a.m. June 27, 2014 - PR Newswire - PRF
Akorn Divests ECR Pharmaceuticals to Valeant 11:11 a.m. June 20, 2014 - BusinessWire - BZX
Aerie Pharmaceuticals Names Craig R. Skenes as Vice President, Business Development 4:05 p.m. June 16, 2014 - BusinessWire - BZX
Pharma Stocks Review -- Research on Akorn, Questcor Pharma, Nektar Therapeutics, and Endocyte 8:00 a.m. June 5, 2014 - PR Newswire - PRF
Financial Results, Acquisition Agreement, and Investor Meeting - Analyst Notes on Zoetis, Horizon Pharma, Akorn, Furiex and Medicines Co. 7:20 a.m. May 16, 2014 - PR Newswire - PRF
Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn 11:30 a.m. May 9, 2014 - PR Newswire - PRF
Akorn to Acquire VersaPharm for $440 Million 9:19 a.m. May 9, 2014 - BusinessWire - BZX
Akorn Reports 2014 First Quarter Results 7:03 a.m. May 6, 2014 - BusinessWire - BZX
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts 8:00 a.m. April 25, 2014 - PR Newswire - PRF
Actavis to Acquire Four Products from Akorn 4:15 p.m. April 17, 2014 - PR Newswire - PRF
Akorn Completes Acquisition of Hi-Tech Pharmacal 9:21 a.m. April 17, 2014 - BusinessWire - BZX
Repligen Corporation Set to Join the S&P SmallCap 600 5:53 p.m. April 15, 2014 - PR Newswire - PRF
(0)
(0)